Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAGOON: Lurbinectedin ± Irinotecan vs Topotecan in Relapsed SCLC
jRCT2071230123Phase 3Active, not recruiting
- Sponsor
- PharmaMar
- Start
- May 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of lurbinectedin in small cell lung cancer (SCLC) (3 arms), sponsored by PharmaMar. Primary endpoint: Overall survival. Started May 2024; status: active, not recruiting.
02
Drugs
lurbinectedin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2071230123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230123.